ReviewBulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies
Keywords
HDV
Bulevirtide
Entry inhibitor
HDV RNA
virological response
combined response
chronic hepatits Delta
compensated cirrhosis
clinically significant portal hypertension
hepatitis D virus
HDV ribonucleic acid
Cited by (0)
Author names in bold designate shared co-first authorship
© 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.